Topics

Companies Related to "Cancer Genetics settles failed merger with NovellusDx" [Most Relevant Company Matches] RSS

17:11 EST 11th December 2019 | BioPortfolio

Here are the most relevant search results for "Cancer Genetics settles failed merger with NovellusDx" found in our extensive corporate database of over 50,000 company records.

Showing "Cancer Genetics settles failed merger with NovellusDx" Companies 1–25 of 2,700+

Extremely Relevant

NovellusDx

A precision oncology company that developed a novel live cell based assay to characterize the activity of unknown cancer mutations and test their response to targeted therapies. NovellusDx helps biopharma throughout the drug life cycle, from target discovery through clinical development to market expansion. More information: www.novellusdx.com.


Relevant

AccessDNA, Inc.

AccessDNA is the leading online consumer resource for genetics. The company combines high-quality content about genetics with access to, and evaluation of, relevant testing, counseling, and support services. By providing valuable insight into the genetics of disease, AccessDNA helps people better understand their treatment, management and prevention option...

Genetics & IVF Institute

Genetics & IVF was the first U.S. center to introduce non-surgical ultrasound guided egg retrieval for IVF Genetics & IVF achieved America's first frozen embryo twin birth Genetics & IVF was the first American center to publicly report pregnancies using ICSI (intracytoplasmic sperm injection) Genetics & IVF was the first to medically test patients for certain mutations which cause hereditary breas...


Ambry Genetics Corporation

Ambry Genetics is a privately held healthcare company with the industry’s most comprehensive suite of genetic testing solutions, benefiting 90% of all U.S. patients covered by public and private insurers. Ambry Genetics is dedicated to scientific collaboration and the belief that human health should not be patented or owned.

Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intell...

deCODE genetics Inc.

In January 2006 deCODE GENETICS Inc., acquired Urdur Verdanki Skuld, a privately-held cancer research firm. The acquisition enables deCODE to broaden and enhances its cancer program by applying deCODE's unique gene discovery and drug development capabilities to an even larger set of population-based resources.

Population Genetics

Harnessing The Power of Populations™ Population Genetics’ approach takes the process of genetic analysis one step further. It enables the elaboration and testing of distinct hypotheses focused on both contiguous and non-contiguous regions of the genome. Whether these have been identified by other technologies such as investigation of gene expression levels, copy number variation, p...

Oncura

On July 1, 2003, a merger between two innovative leaders in prostate cancer treatments set the standard for minimally invasive options. The merger between Amersham Health (now GE Healthcare)–Therapy Business, the leader in brachytherapy and Galil Medical’s Urology Business, the innovator in cryotherapy procedures was finalized. This formed a new company combining both our people and products e...

Cold Genesys Inc.

Cold Genesys, Inc. is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. In 2010, Cold Genesys acquired exclusive worldwide rights to develop CG0070 from BioSante Pharmaceuticals. CG0070 is currently under investigation in a Phase II, single-arm, open-label, pivotal study (BOND II) for patient...

PHARMALITY ENTERPRISES, INC.

Pharmality Enterprises, Inc. began in 2002 as an educational company focusing on delivering the latest pharmaceutical developments to a variety of target audiences. Combining our wealth of knowledge with rigorous training we sought to perfect our speaking methods and expand from mere delivering comprehensive information to motivating and inspiring enthusiasm within the audience towards a particula...

ArborGen Inc.

ArborGen is revolutionizing productivity in forestry. ArborGen is the largest global supplier of seedling products and a leading provider of improved genetics to the forest industry. Through innovations in conventional breeding, improved genetics and emerging biotechnology advances, ArborGen is developing high-value products that significantly improve the ...

ChemGenex Pharmaceuticals

ChemGenex Pharmaceuticals Limited was formed in 2004 from the merger of AGT BioSciences of Melbourne, Australia and ChemGenex Therapeutics of Menlo Park, California USA. ChemGenex Therapeutics was focused on applying genomic technologies to the pre-clinical and clinical development of small molecule therapeutics for the treatment of cancer. AGT BioSciences was focused on discovery and validation o...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

Cancer for College

Cancer for College was formed in 1993 by two-time cancer survivor and double-amputee Craig Pollard. Cancer for College was created to provide hope and inspiration by providing college scholarships to cancer survivors and amputees. Since its inception, Cancer for College has granted nearly $500k in scholarships to more than 400 cancer survivors. For more information about Cancer for College visit w...

Tower Hematology Oncology Medical Group

Tower Hematology Oncology Medical Group was formed in 1991 as the result of a merger between two well-established medical oncology practices that had served patients in Los Angeles for more than 10 years. We are a group of diverse cancer specialists that focus on the full spectrum of oncology and hematology problems. By pooling our knowledge, we are able to provide a strong research-based practic...

Probably Relevant

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.

Sigma Pharmaceuticals Limited

Sigma Pharmaceuticals Limited is the new name of the company listed on the Australian Stock Exchange (ASX) following the merger between Sigma Company Limited and Arrow Pharmaceuticals Limited on 19 December 2005. The ASX code is "SIP".Following the merger, Sigma is now inside the top 75 companies listed on the ASX. The business has expanded to provide a comprehensive service and product offering t...

GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also...

Cancer and Careers

Cancer and Careers is a program committed to changing the face of cancer in the workplace by providing a comprehensive website, free publications, and a series of support groups and educational seminars for employees with cancer. Cancer and Careers' Living and Working with Cancer workbook, available free of charge in English and Spanish, has been distributed to more than 70,000 cancer survivors in...

Cancer Prevention Institute of California

The Cancer Prevention Institute of California (CPIC) is the nation's premier organization dedicated to preventing cancer and to reducing its burden where it cannot yet be prevented. Formerly known as the Northern California Cancer Center, CPIC tracks patterns of cancer throughout the entire population and identifies those at risk for developing cancer. Its research scientists are leaders in inves...

Life Stem Genetics Inc.

Life Stem Genetics (“LSG”) is a progressive health care company that focuses on healing with a patient’s own “Stem Cells”. Stem Cells for years have been known to heal a variety of ailments successfully and now it is being offered as an efficient and painless way to treat many different illnesses ranging from orthopedic Injuries, neurolog...

nTelagent, Inc.

nTelagent, Inc.’s Retail Application for Healthcare is the only point-of-service collection solution for the healthcare industry that settles all accounts on the front end – regardless of whether the patient is insured, uninsured or charity. Similar to applications used in the retail industry at the point of sale, the company’s Web-based sys...

The North Shore-LIJ Cancer Institute

The North Shore-LIJ Cancer Institute is one of the largest cancer providers in the New York metropolitan area. With 200 physicians, the Cancer Institute diagnoses and/or treats more than 16,000 cancer patients each year. Its multidisciplinary teams develop individualized treatment plans that address patients’ physical and emotional needs through 12 di...

Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of t...

Genesis Genomics Inc.

Cancer is the leading cause of pre-mature death in Canada, being responsible for almost 1/3 of all potential years of life lost. During their life-time, 2 in 19 women are expected to develop breast cancer, 1 in 18 will develop colorectal cancer, and 1 in 20 will develop lung cancer. Among men, 1 in 9 will develop prostate cancer during their life-time (National Cancer Institute of Canada, 2000).


More From BioPortfolio on "Cancer Genetics settles failed merger with NovellusDx"

Quick Search

Corporate Database Quicklinks